FUNDS » PRIVATE

Over the past twenty five years, we have provided start-up and growth capital to more than seventy-five companies

Our activities as a dedicated private equity healthcare investor date back to the late 1980s. At that time, providing start-up and growth capital to innovative healthcare companies was not commonplace. In fact, we were one of the first to assume this role. As a result, we have grown to become one of the most experienced healthcare investors in Europe. Over time, we have raised a suite of closed-end investment vehicles that target private companies only, the latest two being LSP 5 and LSP HEF. Combined, we have raised through all our private equity funds more than €1 billion, making it the largest franchise within our firm.

Private LSP Companies in Portfolio Selection of M&A and IPO Transactions of LSP Companies
Orphazyme
Therapies for lysosomal storage - and protein misfolding diseases
Merus - IPO
Innovative cancer treatments
Immunic
Therapies for autoimmune and immunology related diseases
Sapiens – (acquired by Medtronic)
Medical device for treatment of Parkinson's disease
Pharvaris
Development of drug for orphan disease
Curetis - IPO
Ultra-rapid diagnosis of infections
ViCentra
Novel, small insulin patch pump
Kiadis Pharma - IPO
Innovative treatment for blood cancers
eTheRNA
mRNA immunotherapies for oncology and infectious diseases
Seahorse Bioscience (acquired by Agilent Technologies)
Commercialization of medical instruments and laboratory products
G-Therapeutics
Implantable neuro-stimulation system for spinal cord injury
Nexstim - IPO
Medical device for brain stimulation
Luxendo
Light sheet microscopy
Probiodrug - IPO
Development of drugs for Alzheimer's disease
Neuravi
Innovative devices for minimally invasive stroke therapy
Celladon - IPO
Innovative treatments for heart disease
Kuros BioSciences
Orthobiological products for tissue and fracture repair
Activaero – (acquired by Vectura)
Novel medical solutions for lung disease
Xeltis
Spontaneous growth of natural heart valves and vessels
Prosensa - (acquired by BioMarin)
Development of drugs for Duchenne Muscular Dystrophy
Illuminoss
Minimally invasive treatment of bone fractures
ArGEN-X – IPO
Innovative treatments for cancer and other diseases
Ventaleon
Treatment of severe hospitalized Influenza
Okairos - M&A (acquired by GSK)
Breakthrough vaccines for infectious diseases
Rotation Medical
First treatment healing rotator cuff disease
Affimed - IPO
Innovative cancer treatments
Atlas Genetics
Ultra-rapid diagnosis of infections
ActoGeniX (acquired by Intrexon)
Oral delivery of complex biological medicines
Mint Solutions
Prevention of drug misadministration at the bedside
Santarus - IPO followed by M&A (acquired by Salix)
Novel treatments for specialist care
Cardiac Dimensions
Minimally invasive reshaping of heart valve
Syntaxin - M&A (acquired by Ipsen)
Novel treatment options for pain and inflammation
Sequana Medical
Treatment of improper fluid balances in the body
Octoplus - IPO followed by M&A (acquired by Dr Reddy)
Preparation and development of injectable drugs
Harvest Automation
Advanced robotic platforms
Affectis (acquired by LDC)
Novel drugs for psychiatric disorders
Cobalt
Development of next generation biobutanol
Pasteuria - M&A (acquired by Syngenta)
Advanced crop protection technologies
EyeSense
Next-generation glucose measuring devices
BMEye - M&A (acquired by Edwards)
Commercialization of cardiovascular monitoring devices
ISTO
Highly innovative repair of damaged knees and spinal discs
DevGen - IPO followed by M&A (acquired by Syngenta)
Next-generation crop protection
Cellerix - M&A (acquired by Tigenix)
Innovative treatments for bowel disorders and other diseases
Crucell - IPO followed by M&A (acquired by J&J)
Development of vaccines
Flowcardia - M&A (acquired by C.R. Bard)
State-of-the-art medical devices for heart disease
Movetis - IPO followed by M&A (acquired by Shire)
Innovative treatments for bowel disease
Zealand Pharma - IPO
Novel treatment options for diabetes and other diseases
IDEA - M&A (acquired by Alpharma)
Delivery of advanced drugs through the skin
U3 Pharma - M&A (acquired by Daiichi Sankyo)
Innovative cancer treatments
4-Antibody - M&A (Acquired by Agenus)
Innovative cancer treatments
Attune Foods - M&A (acquired by Post foods)
Commercialization of probiotic foodbars
Jerini Pharma - IPO followed by M&A (acquired by Shire)
Development of drug for rare and fatal disease
Rhein Biotech - IPO followed by M&A (acquired by Berna)
Commercialization of vaccines for infectious disease
Hybrigenics - IPO
Advanced platform technologies to enable the development of drugs
MDxHealth - IPO
Highly specific detection of tumors
Kudos - M&A (acquired by Astra Zeneca)
Innovative cancer treatments
BioXell - IPO followed by M&A (acquired by Cosmo)
Novel drugs for bladder disorders and inflammatory diseases
DNAge - M&A (acquired by Pharming)
Products for medical problems associated with aging
Ness - M&A (acquired by Bioness)
Innovative rehabilitation products
Sequenom - IPO
Precise identification of diseases and disorders in humans
Quadrant - IPO
Drug formulation
Pharming - IPO
Development of drugs for rare and serious diseases
Introgene - M&A (merged with U-Bisys into Crucell)
Development of vaccines
Qiagen - IPO
Diagnostics and laboratory testing equipment
Biora - M&A (acquired by Straumann)
Commercialization of products used by dentists and oral surgeons
U-Bisys - M&A (merged with Introgene into Crucell)
Innovative drug development platform
Kreatech - M&A (acquired by Leica)
Labeling and detection of biological molecules
read less

LSP 5 Fund

Our LSP 5 fund was launched in late 2014 (here is the press release). It is the successor fund to our previous closed-end investment funds that we have raised over the past 15 years. Through the years, we have stuck to the same and proven investment strategy and focus. LSP 5, just like its predecessors, targets investments in healthcare companies developing novel and ground-breaking products and technologies that provide solutions to unmet medical needs. This strategy and focus has paved the way for LSP to become one of Europe’s foremost names in healthcare investing.
read more

LSP 5 and its predecessor funds represent the largest franchise within our firm. It has allowed us to become one of Europe’s prime names in healthcare investing

Over the years, we have supported the development of numerous companies, providing them with the capital required to grow and flourish. Typically, we adopt an active, hands-on approach to our investments. We often work closely with company management teams, co-directors and major co-investors in an effort to achieve the long-term goals that we set together from the outset. Our investments are primarily located in Europe but also in the US, and made at various stages of a company's development. Historically, we have made seed investments in assets at the research phase and formed companies from them. We also make later-stage investments requiring less intense guidance and support, and simply more capital. In addition, we have also made many investments in companies that were spun out from large pharmaceutical companies around assets that were no longer deemed of strategic interest to the parent companies. The LSP 5 fund targets to make up to 15 investments. Like all its predecessor funds, LSP 5 will appeal to investors who wish to invest in private equity and in a sector that strives to create breakthrough products and technologies that make a very real difference to patients. Typical investors include large institutions, fund-of-funds, family offices, high net worth individuals and strategic investors such as pharmaceutical companies.

People who have questions about our funds and would like to receive more information, are kindly asked to email René Kuijten at rkuijten@lspvc.com; alternatively, please contact one of our offices via +31 (20) 664 55 00 (Amsterdam), +49 (0) 89 330 666 0 (Munich) or +1 (781) 472-2740 (Boston) and we will ensure you are connected with René Kuijten or one of his colleagues with direct management responsibilities of the fund in question.
read less

LSP HEF FUND

Our LSP Health Economics Fund (LSP HEF) was launched in 2012. At its start, it received a €50 million cornerstone investment from Achmea, the largest healthcare insurance company in The Netherlands. This was soon followed by an investment by another large strategic investor called Menzis and later by a number of large family offices and other (semi-) institutional investors. The fund’s strategy is to invest in late-stage private healthcare companies that have products on the market or are very close to market introduction. Contrary to our other funds, the LSP HEF Fund does not invest in companies that develop drugs.
read more

The LSP HEF fund only invests in those companies that have products or technologies that not only improve the quality of healthcare, but reduce its cost at the same time

It focuses exclusively on investments in healthcare companies that have developed products in the areas of medical devices and diagnostics, or in areas where IT provides solutions for healthcare related problems. Crucially, the fund only invests in those companies that have products or technologies that improve the quality of healthcare, while reducing its cost at the same time. This is generally referred to as strong “health economics case” and such companies are, for that reason, of high interest to patients, care providers and to society at large.

A prime example of such a case and an actual investment of the LSP Health Economics Fund is IlluminOss (www.illuminoss.com). This is a company that has developed a technology that offers a radically new approach to the treatment of bone fractures. The approach allows for an overall cost saving of 25% per patient and, in contrast to the standard of care, is minimally invasive. It leaves only a small scar, does not require a cast, reduces complications significantly and limits hospital stays. For those reasons, it offers huge advantages not only to patients, but also to the cost-efficiency of the healthcare system.

People who have questions about our funds and would like to receive more information, are kindly asked to email Rudy Dekeyser at eqrxrlfre@yfcip.pbz; alternatively, please contact one of our offices via +31 (20) 664 55 00 (Amsterdam), +49 (0) 89 330 666 0 (Munich) or +1 (781) 472-2740 (Boston) and we will ensure you are connected with Rudy Dekeyser or one of his colleagues with direct management responsibilities of the fund in question.
read less

FUNDS » PRIVATE

Over the past twenty five years, we have provided start-up and growth capital to more than seventy-five companies

Our activities as a dedicated private equity healthcare investor date back to the late 1980s. At that time, providing start-up and growth capital to innovative healthcare companies was not commonplace. In fact, we were one of the first to assume this role. As a result, we have grown to become one of the most experienced healthcare investors in Europe. Over time, we have raised a suite of closed-end investment vehicles that target private companies only, the latest two being LSP 5 and LSP HEF. Combined, we have raised through all our private equity funds more than € 600 million, making it the largest franchise within our firm.

Private LSP Companies in Portfolio Selection of M&A and IPO Transactions of LSP Companies
Orphazyme
Therapies for lysosomal storage - and protein misfolding diseases
Merus - IPO
Innovative cancer treatments
Immunic
Therapies for autoimmune and immunology related diseases
Sapiens – (acquired by Medtronic)
Medical device for treatment of Parkinson's disease
Pharvaris
Development of drug for orphan disease
Curetis - IPO
Ultra-rapid diagnosis of infections
ViCentra
Novel, small insulin patch pump
Kiadis Pharma - IPO
Innovative treatment for blood cancers
eTheRNA
mRNA immunotherapies for oncology and infectious diseases
Seahorse Bioscience (acquired by Agilent Technologies)
Commercialization of medical instruments and laboratory products
G-Therapeutics
Implantable neuro-stimulation system for spinal cord injury
Nexstim - IPO
Medical device for brain stimulation
Luxendo
Light sheet microscopy
Probiodrug - IPO
Development of drugs for Alzheimer's disease
Neuravi
Innovative devices for minimally invasive stroke therapy
Celladon - IPO
Innovative treatments for heart disease
Kuros BioSciences
Orthobiological products for tissue and fracture repair
Activaero – (acquired by Vectura)
Novel medical solutions for lung disease
Xeltis
Spontaneous growth of natural heart valves and vessels
Prosensa - (acquired by BioMarin)
Development of drugs for Duchenne Muscular Dystrophy
Illuminoss
Minimally invasive treatment of bone fractures
ArGEN-X – IPO
Innovative treatments for cancer and other diseases
Ventaleon
Treatment of severe hospitalized Influenza
Okairos - M&A (acquired by GSK)
Breakthrough vaccines for infectious diseases
Rotation Medical
First treatment healing rotator cuff disease
Affimed - IPO
Innovative cancer treatments
Atlas Genetics
Ultra-rapid diagnosis of infections
ActoGeniX (acquired by Intrexon)
Oral delivery of complex biological medicines
Mint Solutions
Prevention of drug misadministration at the bedside
Santarus - IPO followed by M&A (acquired by Salix)
Novel treatments for specialist care
Cardiac Dimensions
Minimally invasive reshaping of heart valve
Syntaxin - M&A (acquired by Ipsen)
Novel treatment options for pain and inflammation
Sequana Medical
Treatment of improper fluid balances in the body
Octoplus - IPO followed by M&A (acquired by Dr Reddy)
Preparation and development of injectable drugs
Harvest Automation
Advanced robotic platforms
Affectis (acquired by LDC)
Novel drugs for psychiatric disorders
Cobalt
Development of next generation biobutanol
Pasteuria - M&A (acquired by Syngenta)
Advanced crop protection technologies
EyeSense
Next-generation glucose measuring devices
BMEye - M&A (acquired by Edwards)
Commercialization of cardiovascular monitoring devices
ISTO
Highly innovative repair of damaged knees and spinal discs
DevGen - IPO followed by M&A (acquired by Syngenta)
Next-generation crop protection
Cellerix - M&A (acquired by Tigenix)
Innovative treatments for bowel disorders and other diseases
Crucell - IPO followed by M&A (acquired by J&J)
Development of vaccines
Flowcardia - M&A (acquired by C.R. Bard)
State-of-the-art medical devices for heart disease
Movetis - IPO followed by M&A (acquired by Shire)
Innovative treatments for bowel disease
Zealand Pharma - IPO
Novel treatment options for diabetes and other diseases
IDEA - M&A (acquired by Alpharma)
Delivery of advanced drugs through the skin
U3 Pharma - M&A (acquired by Daiichi Sankyo)
Innovative cancer treatments
4-Antibody - M&A (Acquired by Agenus)
Innovative cancer treatments
Attune Foods - M&A (acquired by Post foods)
Commercialization of probiotic foodbars
Jerini Pharma - IPO followed by M&A (acquired by Shire)
Development of drug for rare and fatal disease
Rhein Biotech - IPO followed by M&A (acquired by Berna)
Commercialization of vaccines for infectious disease
Hybrigenics - IPO
Advanced platform technologies to enable the development of drugs
MDxHealth - IPO
Highly specific detection of tumors
Kudos - M&A (acquired by Astra Zeneca)
Innovative cancer treatments
BioXell - IPO followed by M&A (acquired by Cosmo)
Novel drugs for bladder disorders and inflammatory diseases
DNAge - M&A (acquired by Pharming)
Products for medical problems associated with aging
Ness - M&A (acquired by Bioness)
Innovative rehabilitation products
Sequenom - IPO
Precise identification of diseases and disorders in humans
Quadrant - IPO
Drug formulation
Pharming - IPO
Development of drugs for rare and serious diseases
Introgene - M&A (merged with U-Bisys into Crucell)
Development of vaccines
Qiagen - IPO
Diagnostics and laboratory testing equipment
Biora - M&A (acquired by Straumann)
Commercialization of products used by dentists and oral surgeons
U-Bisys - M&A (merged with Introgene into Crucell)
Innovative drug development platform
Kreatech - M&A (acquired by Leica)
Labeling and detection of biological molecules
read less

LSP 5 Fund

Our LSP 5 fund was launched in late 2014 (here is the press release). It is the successor fund to our previous closed-end investment funds that we have raised over the past 15 years. Through the years, we have stuck to the same and proven investment strategy and focus. LSP 5, just like its predecessors, targets investments in healthcare companies developing novel and ground-breaking products and technologies that provide solutions to unmet medical needs. This strategy and focus has paved the way for LSP to become one of Europe’s foremost names in healthcare investing.
read more

LSP 5 and its predecessor funds represent the largest franchise within our firm. It has allowed us to become one of Europe’s prime names in healthcare investing

Over the years, we have supported the development of numerous companies, providing them with the capital required to grow and flourish. Typically, we adopt an active, hands-on approach to our investments. We often work closely with company management teams, co-directors and major co-investors in an effort to achieve the long-term goals that we set together from the outset. Our investments are primarily located in Europe but also in the US, and made at various stages of a company's development. Historically, we have made seed investments in assets at the research phase and formed companies from them. We also make later-stage investments requiring less intense guidance and support, and simply more capital. In addition, we have also made many investments in companies that were spun out from large pharmaceutical companies around assets that were no longer deemed of strategic interest to the parent companies. The LSP 5 fund targets to make up to 15 investments. Like all its predecessor funds, LSP 5 will appeal to investors who wish to invest in private equity and in a sector that strives to create breakthrough products and technologies that make a very real difference to patients. Typical investors include large institutions, fund-of-funds, family offices, high net worth individuals and strategic investors such as pharmaceutical companies.

People who have questions about our funds and would like to receive more information, are kindly asked to email René Kuijten at rkuijten@lspvc.com; alternatively, please contact one of our offices via +31 (20) 664 55 00 (Amsterdam), +49 (0) 89 330 666 0 (Munich) or +1 (781) 472-2740 (Boston) and we will ensure you are connected with René Kuijten or one of his colleagues with direct management responsibilities of the fund in question.
read less

LSP HEF FUND

Our LSP Health Economics Fund (LSP HEF) was launched in 2012. At its start, it received a €50 million cornerstone investment from Achmea, the largest healthcare insurance company in The Netherlands. This was soon followed by an investment by another large strategic investor called Menzis and later by a number of large family offices and other (semi-) institutional investors. The fund’s strategy is to invest in late-stage private healthcare companies that have products on the market or are very close to market introduction. Contrary to our other funds, the LSP HEF Fund does not invest in companies that develop drugs.
read more

The LSP HEF fund only invests in those companies that have products or technologies that not only improve the quality of healthcare, but reduce its cost at the same time

It focuses exclusively on investments in healthcare companies that have developed products in the areas of medical devices and diagnostics, or in areas where IT provides solutions for healthcare related problems. Crucially, the fund only invests in those companies that have products or technologies that improve the quality of healthcare, while reducing its cost at the same time. This is generally referred to as strong “health economics case” and such companies are, for that reason, of high interest to patients, care providers and to society at large.

A prime example of such a case and an actual investment of the LSP Health Economics Fund is IlluminOss (www.illuminoss.com). This is a company that has developed a technology that offers a radically new approach to the treatment of bone fractures. The approach allows for an overall cost saving of 25% per patient and, in contrast to the standard of care, is minimally invasive. It leaves only a small scar, does not require a cast, reduces complications significantly and limits hospital stays. For those reasons, it offers huge advantages not only to patients, but also to the cost-efficiency of the healthcare system.

People who have questions about our funds and would like to receive more information, are kindly asked to email Rudy Dekeyser at eqrxrlfre@yfcip.pbz; alternatively, please contact one of our offices via +31 (20) 664 55 00 (Amsterdam), +49 (0) 89 330 666 0 (Munich) or +1 (781) 472-2740 (Boston) and we will ensure you are connected with Rudy Dekeyser or one of his colleagues with direct management responsibilities of the fund in question.
read less